Pharmacological distinction between soluble and transmembrane adenylyl cyclases.

TitlePharmacological distinction between soluble and transmembrane adenylyl cyclases.
Publication TypeJournal Article
Year of Publication2013
AuthorsBitterman JL, Ramos-Espiritu L, Diaz A, Levin LR, Buck J
JournalJ Pharmacol Exp Ther
Volume347
Issue3
Pagination589-98
Date Published2013 Dec
ISSN1521-0103
KeywordsAdenylyl Cyclase Inhibitors, Adenylyl Cyclases, Cells, Cultured, Cyclic AMP, Dose-Response Relationship, Drug, Enzyme Inhibitors, HEK293 Cells, Humans, Membrane Proteins, Signal Transduction, Subcellular Fractions, Substrate Specificity
Abstract

The second messenger cAMP is involved in a number of cellular signaling pathways. In mammals, cAMP is produced by either the hormonally responsive, G protein-regulated transmembrane adenylyl cyclases (tmACs) or by the bicarbonate- and calcium-regulated soluble adenylyl cyclase (sAC). To develop tools to differentiate tmAC and sAC signaling, we determined the specificity and potency of commercially available adenylyl cyclase inhibitors. In cellular systems, two inhibitors, KH7 and catechol estrogens, proved specific for sAC, and 2',5'-dideoxyadenosine proved specific for tmACs. These tools provide a means to define the specific contributions of the different families of adenylyl cyclases in cells and tissues, which will further our understanding of cell signaling.

DOI10.1124/jpet.113.208496
Alternate JournalJ. Pharmacol. Exp. Ther.
PubMed ID24091307
PubMed Central IDPMC3836311
Grant ListT32 GM073546 / GM / NIGMS NIH HHS / United States
R01 GM062328 / GM / NIGMS NIH HHS / United States
R01 HD059913 / HD / NICHD NIH HHS / United States
HD059913 / HD / NICHD NIH HHS / United States
GM62328 / GM / NIGMS NIH HHS / United States